Synthesis, Reactions and Biological Evaluation of Some Novel 5-Bromobenzofuran-Based Heterocycles

Ahmed Hamdy Halawa^1,

¹Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt

Cite this paper:
Ahmed Hamdy Halawa. Synthesis, Reactions and Biological Evaluation of Some Novel 5-Bromobenzofuran-Based Heterocycles. World Journal of Organic Chemistry. 2014; 2(1):9-17. doi: 10.12691/wjoc-2-1-2

Abstract

Condensation of 2-acetyl-5-bromobenzofuran with hydrazine derivatives 2a,b afforded hydrazone derivatives 3a,b, which reacted with alkyl halides4a,b to yield ethylidene derivatives 5a,b. Also, 3a reacted with hydrazonyl halides6a,b to give 1,3,4-thiadiazole derivatives 9a,b. Thiosemicarbazone3b was reacted with acetic anhydride and halogenated compounds to afford the corresponding heterocyclic derivatives 10, 11a,b, 12-17 and 18a,b.Moreover, interaction of 16 with tetracyanoethylene and salicyldehyde derivatives furnished 24 and 26a,b, respectively. Finally, reaction of 16 with DMF-DMA afforded enaminone29, which on treatment with different heterocyclic amines yielded 31 and 33 respectively. Some of the newly synthesized compounds showed promising antimicrobial activity.

Keywords:
benzofuran 134-thiadiazole thiazolidinone thiazole antimicrobial

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Keay, B. A.; Dibble, P. W.; In Comprehensive Heterocyclic Chemistry II-A Review of the Literature 1982-1995; Pergamon: New York, 1996, 2, 413-436.
[2]	A) Powers, L. J.; J. Med. Chem. 1976, 19, 57-62. (B) Lambert, C. M.; Ple, P.; PCT Int. Appl. WO 0230, 924; Chem. Abstr. 2002, 136, 325553d.
[3]	Hayakawa, I.; Shioya, R.; Agatsuma, T.; Furukawa, H.; Sugano, Y.; Bioorg. Med. Chem. Lett. 2004, 14, 3411-3414.
[4]	Santana, L.; Teijeira, M.; Uriarte, E.; Teran, C.; Linares, B.; Villar, R.; Laguna, R.; Cano, E.; Eur. J. Pharm. Sci. 1999, 7, 161-166.
[5]	Sangapure, S.; Basawaraj, R.; Indian J. Pharm. Sci. 2004, 66, 221-225.
[6]	Findlay, J.; Buthetezi, S.; Seveck, M.; Miller, J.; J. Nat. Prod. 1997, 60, 1214-1215.
[7]	Masubuchi, M.; Ebiike, H.; Kawasaki, K.; Sogabe, S.; Morikami, K.; Shiratori, Y.; Tsujii, S.; Fujii, T.; Sakata, K.; Hayase, M.; Shindoh, H.; Aoki, Y.; Ohtsuka, T.; Shimma, N.; Bioorg. Med. Chem. 2003, 11, 4463-4478.
[8]	Richardson, D.R.; Iron chelators as therapeutic agents for the treatment of cancer, Crit. Rev. Oncol. Hematol. 2002, 42, 267-281.
[9]	Lovejoy, D.B.; Richardson, D.R.; Novel “hybrid” iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells, Blood. 2002, 100, 666-676.
[10]	Belicchi-Ferrari, M.; Isceglie, F.; Casoli, C.; Durot, S.; Morgenstern-Badarau, I.; Pelosi, G.; Pilotti, E.; Pinelli, S.; Tarasconi, P.; Copper (II) and Cobalt (III) pyridoxal thiosemicarbazone complexes with nitroprusside as counterion: syntheses, electronic properties, and antileukemic activity, J. Med. Chem. 2005, 48, 1671-1675.
[11]	Greenbaum, D.C.; Mackey, Z.; Hansell, E.; Doyle, P.; Gut, J.; Caffrey, C.R.; Lehrman, J.; Rosenthal, P.J.; McKerrow, J.H.; Chibale, K.; J. Med. Chem. 2004, 47, 3212-3219.
[12]	Pirrung, M.C.; Pansare, S.V., Sarma, K.D.; Keith, K.A.; Kern, E.R.; J. Med. Chem. 2005, 48, 3045-3050.
[13]	Oh, C. H.; Cho, H. W.; Baek, D.; Cho, J. H. Eur. J. Med. Chem. 2002, 37, 743.
[14]	Holla, B. S.; Malini, K. V.; Rao, B. S.; Sarojini, B. K.; Kumari, N. S. Eur. J. Med. Chem. 2003, 38, 313.
[15]	Kritsanida, M.; Mouroutsou, A.; Marakos, P.; Pouli, N.; Papakonstantinou-Garoufalias, S.; Pannecouque, C.; Witvrouw, M.; Clercq, E. D. IL Farmaco 2002, 57, 253.
[16]	Andreani, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.;Rambaldi, M. Eur. J. Med. Chem. 2001, 36, 743.
[17]	Foroumadi, A.; Asadipour, A.; Mirzaei, M.; Karimi, J.; Emami, S. IL Farmaco 2002, 57, 765.
[18]	Gu, X. H.; Wan, X. Z.; Jiang, B. Bioorg. Med. Chem. Lett. 1999, 9, 569.
[19]	Jiang, B.; Gu, X. H. Bioorg. Med. Chem. 2000, 8, 363.
[20]	Bolos, C. A.; Papazisis, K. T.; Kortsaris, A. H.; Voyatzi, S.; Zambouli, D.; Kyriakidis, D. A. J. Inorg. Biochem. 2002, 88, 25.
[21]	Tapia, R. A.; Alegria, L.; Pessoa, C. D.; Salas, C.; Corte´s, M. J.; Valderrama, J. A.; Sarciron, M. E.; Pautet, F.; Walchshofer, N.; Fillion, H. Bioorg. Med. Chem. 2003, 11, 2175.
[22]	Ijichi, K.; Fujiwara, M.; Nagano, H.; Matsumoto, Y.; Hanasaki, Y.; Ide, T.; Katsuura, K.; Takayama, H.; Shirakawa, S.; Aimi, N.; Shigeta, S.; Konno, K.; Matsushima, M.; Yokota, T.; Baba, M. Antiviral Res. 1996, 31, 87.
[23]	Bedair, A. H. ; Abd el-wahab, A. H. F. ; El-agrody, A. M. ; Ali, F. M. ; Halawa, A. H. and El-sherbiny, G. M. ; J. Serb. Chem. Soc. 2006, 71 (5) 459-469.
[24]	Abd el-wahab, A. H. F. ; Al-Fifi, Z. A. ; Bedair, A. H. ; Ali, F. M. ; Halawa, A. H. and El-agrody, A. M. ; Molecules 2011, 16, 307-318.
[25]	Hanamanthsa, S. B. and Virupax, V. B.; J. Heterocycl. Chem 1982, 19, 69.
[26]	Klayman, D. L.; Bartosevichm, J. F.; Gtiffin, T. S. ; Mason, C. J. and Scovill, J. P.; J. of Med. Chem. 1979, 22, 855.
[27]	Shawali, A. S.; Abdelhamid, A. O.; Bulletin of the chemical society of Japan. 1976, 49, 321.
[28]	Sommen G.; Comel A.; and Kirsch G., Tetrahedron lett., 2002, 43, 257.
[29]	Röhrkasten, R.; Raatz, P.;kreher, R. P. And Balaszkewicz, M.; Z. Nature-forsch, 1997, 52b, 1526.
[30]	Hafiz, I. S.;Z. Naturforsch, 2000, 55b, 321.
[31]	European Committee for Antimicrobial SusceptibilityTesting (EUCAST) of the European Society of Clinical Microbiology andInfectious Diseases (ESCMID). Clinical Microbiology and Infection, Vol. 6 Number 9, September 2000, pp: 509.
[32]	National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th edn.Approved Standard M7-A5.Wayne, PA: NCCLS, 2000.